

US drugmaker to withdraw cancer-causing weight loss drug

Eisai Co. will withdraw its weight-loss drug Belviq after the US Food and Drug Administration said clinical trials showed an increased incidence of cancer among users. The potential risk of cancer associated with the drug outweighs the benefit of treatment, Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said.